On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

SPAC Merger Fires Boosters for 180 Life Sciences’ Exploration in Unmet Medical Needs of Anti-inflammatories Space

  • Biotechnology company 180 Life Sciences has launched a variety of advanced clinical and preclinical-stage efforts to develop novel anti-inflammatory treatments for patients with chronic illnesses
  • A planned merger with 180 Life Sciences advanced under a special purpose acquisition corporation (SPAC) is expected to be completed within the next month, resulting in a Nasdaq filing under the ticker ATNF
  • 180 Life Sciences’s founders are an experienced team of medical scientists who pioneered anti-inflammatory pharmaceuticals in the 1990s that are still in use today, generating billions in revenue
  • The company’s own-IP clinical trials seek to resolve inflammation-related issues in conditions such as Dupuytren’s disease, frozen shoulder, arthritis, ulcerative colitis, liver fibrosis and nonalcoholic steatohepatitis
  • Analysts forecast the anti-inflammatory therapeutics market will be worth $191.42 billion by 2027, growing at a CAGR of 3 percent

Clinical stage biotechnology company 180 Life Sciences Corp., whose scientific teams are led by drug developers renowned for producing some of the largest-selling pharmaceuticals to ever come to market, is accelerating toward a planned Nasdaq launch under a special purpose acquisition corporation (“SPAC”) that expects to rocket its research into novel anti-inflammatory therapies toward some stellar goals.

KBL Merger Corp. (NASDAQ: KBLM, NASDAQ: KBLMR, and NASDAQ: KBLMW), previously announced its SPAC merger plans with 180 Life Sciences to create a company to be trading under the ticker ATNF (https://ibn.fm/JUoEd), with closing anticipated by November (https://ibn.fm/POsZo). The company recently successfully closed bridge financing for working capital to advance its efforts to go public and develop its pipeline of important new pharmaceuticals.

Following U.S. Securities and Exchange Commission (“SEC”) approval of the company’s S4 registration statement earlier this month, the company organized a special meeting of stockholders for Oct. 26 regarding the business combination.

The clinical trial pipeline includes a Phase 2b/3 trial expected to result in data read-out in 2021 for therapies to fight early-stage Dupuytren’s disease, a condition in which one or more fingers become permanently bent in a flexed position.

Additional Phase 2 trials already  expected to be intiated by year-end or early 2021 include treatment of frozen shoulder, a common condition characterized by stiffness and severe pain in the shoulder joint.

Additonal planned  trails include an immune system suppression therapy to tackle Postoperative Cognitive Dysfunction (POCD), a condition manifesting as a long-lasting cognitive decline after surgery that is regarded as a major clinical problem with no clear cause or effective therapy at this point, although neuroinflammation is understood to play a critical role (https://ibn.fm/U3SJM).

These advanced trials involve the development of products to treat unmet medical needs through anti-TNF therapy, which seeks to block the activity of a substance in the body that can cause inflammation and lead to immune-system diseases.

The company also has begun preclinical studies looking at treatments for liver fibrosis and nonalcoholic steatohepatitis, inflammation-related pain, early arthritis and ulcerative colitis in ex-smokers, all with anticipated inflammatory system tie-ins.

“Our scientific team has unparalleled expertise and a proven track record of developing unique drugs that improved the lives of millions of people and created companies that were later sold for billions of dollars,” KBL Merger Corp. CEO Dr. Marlene Krauss stated in the June news release about the planned ATNF merger. “We have assembled this world-class team to build a unique, global biotechnology company dedicated to developing novel drugs in a cost-effective manner.”

Krauss has invested more than $1 billion through three institutional venture capital funds, numerous IPOs and three prior SPACS, with the current venture marking her fourth SPAC in the healthcare space.

The medical scientist founders of 180 Life Sciences Krauss referred to are pioneers in the field of anti-inflammatory drugs, developing anti-TNF biologics and anti-integrin inhibitors in 1990s that are still on the market, spawning a new class of inflammation therapeutics.

For more information, visit the company’s website at www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://ibn.fm/180

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered